Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.
Asceneuron has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in July 2024.
Asceneuron's investors include Novo Holdings, OrbiMed, Sofinnova Partners, Kurma Partners, SR One.
Asceneuron is headquartered in Lausanne, Switzerland.
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.
Asceneuron is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Asceneuron — Funding & Investors." VCBacked, July 16, 2024, https://www.vcbacked.co/company/asceneuron. Accessed September 30, 2026.
VCBacked. (2024). Asceneuron — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/asceneuron
{{cite web |title=Asceneuron — Funding & Investors |url=https://www.vcbacked.co/company/asceneuron |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated